Thalidomide in ankylosing spondylitis

被引：0
作者：
Huang, F
Wei, JCC
Breban, M
机构：
[1] Hop Cochin, INSERM, U567, F-75014 Paris, France
[2] Hop Cochin, Serv Rhumatol B, F-75014 Paris, France
[3] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2002年 / 20卷 / 06期
关键词：
ankylosing spondylitis; spondylarthropathy; thalidomide; TNF alpha;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Despite potential side effects dominated by teratogenicity and peripheral neuropathy, thalidomide has recently been used to treat severe ankylosing spondylitis (AS). Over 50 patients have been treated across several 6-12 month open studies. Altogether 68% of the patients improved and the drop-out rate was 19%. Inhibition of NF-kappaB and/or TNFalpha is a putative mechanism for thalidomide efficacy in AS.
引用
收藏
页码：S158 / S161
页数：4
相关论文
共 23 条
[1]  
Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO
[2]  
2-F
[3]  
Brandt J, 2000, ARTHRITIS RHEUM-US, V43, P1346, DOI 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO
[4]  
2-E
[5]   USE OF IMMUNOHISTOLOGIC AND IN-SITU HYBRIDIZATION TECHNIQUES IN THE EXAMINATION OF SACROILIAC JOINT BIOPSY SPECIMENS FROM PATIENTS WITH ANKYLOSING-SPONDYLITIS [J].
BRAUN, J ;
BOLLOW, M ;
NEURE, L ;
SEIPELT, E ;
SEYREKBASAN, F ;
HERBST, H ;
EGGENS, U ;
DISTLER, A ;
SIEPER, J .
ARTHRITIS AND RHEUMATISM, 1995, 38 (04) :499-505
[6]  
Breban M, 1999, ARTHRITIS RHEUM, V42, P580, DOI 10.1002/1529-0131(199904)42:3<580::AID-ANR27>3.3.CO
[7]  
2-4
[8]  
Breban M, 2001, ARTHRITIS RHEUM, V44, P2457
[9]   Thalidomide: Current and potential clinical applications [J].
Calabrese, L ;
Fleischer, AB .
AMERICAN JOURNAL OF MEDICINE, 2000, 108 (06) :487-495
[10]  
CHEN TL, 1989, DRUG METAB DISPOS, V17, P402
123